• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

PI3K inhibitors for cancer treatment: five years of preclinical and clinical research after BEZ235.

作者信息

Maira Sauveur-Michel

机构信息

Novartis Institute for Biomedical Research, Oncology Disease Area, Klybeckstrasse 141, Basel, 4002, Switzerland.

出版信息

Mol Cancer Ther. 2011 Nov;10(11):2016. doi: 10.1158/1535-7163.MCT-11-0792.

DOI:10.1158/1535-7163.MCT-11-0792
PMID:22072802
Abstract
摘要

相似文献

1
PI3K inhibitors for cancer treatment: five years of preclinical and clinical research after BEZ235.用于癌症治疗的PI3K抑制剂：BEZ235之后的五年临床前和临床研究
Mol Cancer Ther. 2011 Nov;10(11):2016. doi: 10.1158/1535-7163.MCT-11-0792.
2
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.NVP-BEZ235的鉴定与特性研究，一种新型口服有效的双磷脂酰肌醇3激酶/雷帕霉素哺乳动物靶点抑制剂，具有强大的体内抗肿瘤活性。
Mol Cancer Ther. 2008 Jul;7(7):1851-63. doi: 10.1158/1535-7163.MCT-08-0017. Epub 2008 Jul 7.
3
Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.口服生物可利用的双磷脂酰肌醇3激酶/雷帕霉素哺乳动物靶标抑制剂NVP-BEZ235的抗骨髓瘤活性
Cancer Res. 2009 Jul 15;69(14):5835-42. doi: 10.1158/0008-5472.CAN-08-4285. Epub 2009 Jul 7.
4
Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.NVP-BEZ235 对 PI3K 和 mTORC1/2 信号的双重抑制作用作为急性髓系白血病的一种新的治疗策略。
Clin Cancer Res. 2010 Nov 15;16(22):5424-35. doi: 10.1158/1078-0432.CCR-10-1102. Epub 2010 Sep 30.
5
Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235.通过PI3K/mTOR抑制剂BEZ235增加BIM表达来调节儿童T细胞急性淋巴细胞白血病中的糖皮质激素抵抗
Clin Cancer Res. 2016 Feb 1;22(3):621-32. doi: 10.1158/1078-0432.CCR-15-0114. Epub 2015 Jun 16.
6
Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.双重PI3K和mTOR抑制剂NVP-BEZ235联合甲磺酸伊马替尼对慢性粒细胞白血病细胞系的疗效。
Drug Des Devel Ther. 2017 Apr 3;11:1115-1126. doi: 10.2147/DDDT.S132092. eCollection 2017.
7
The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor.新型磷酸肌醇 3-激酶-雷帕霉素靶蛋白抑制剂 BEZ235 可规避肝细胞生长因子引发的表皮生长因子受体突变型肺癌细胞对厄洛替尼的耐药性。
Int J Cancer. 2013 Jul 15;133(2):505-13. doi: 10.1002/ijc.28034. Epub 2013 Feb 12.
8
Efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 in a preclinical model of adrenocortical carcinoma.新型双重 PI3-激酶/mTOR 抑制剂 NVP-BEZ235 在肾上腺皮质癌的临床前模型中的疗效。
Mol Cell Endocrinol. 2012 Nov 25;364(1-2):101-4. doi: 10.1016/j.mce.2012.08.014. Epub 2012 Aug 31.
9
The PI3K/mTOR dual inhibitor BEZ235 suppresses proliferation and migration and reverses multidrug resistance in acute myeloid leukemia.PI3K/mTOR双重抑制剂BEZ235抑制急性髓系白血病的增殖和迁移并逆转多药耐药性。
Acta Pharmacol Sin. 2017 Mar;38(3):382-391. doi: 10.1038/aps.2016.121. Epub 2017 Jan 2.
10
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.NVP-BEZ235，一种双PI3K/mTOR抑制剂，可阻止PI3K信号传导并抑制具有激活PI3K突变的癌细胞的生长。
Cancer Res. 2008 Oct 1;68(19):8022-30. doi: 10.1158/0008-5472.CAN-08-1385.

引用本文的文献

1
mutations contribute to fulvestrant resistance in ER-positive breast cancer.突变导致雌激素受体阳性乳腺癌对氟维司群耐药。
Am J Transl Res. 2019 Sep 15;11(9):6055-6065. eCollection 2019.
2
Pharmacologic characterization of SHR8443, a novel dual inhibitor of phosphatidylinositol 3-kinase and mammalian target of rapamycin.新型磷脂酰肌醇3激酶和雷帕霉素哺乳动物靶点双重抑制剂SHR8443的药理学特性
Oncotarget. 2017 Nov 14;8(64):107977-107990. doi: 10.18632/oncotarget.22439. eCollection 2017 Dec 8.
3
Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer.
全激酶组RNA干扰筛选揭示了PDK1在雌激素受体阳性乳腺癌对CDK4/6抑制的获得性耐药中的作用。
Cancer Res. 2017 May 1;77(9):2488-2499. doi: 10.1158/0008-5472.CAN-16-2653. Epub 2017 Mar 1.
4
Subcellular localization of FOXO3a as a potential biomarker of response to combined treatment with inhibitors of PI3K and autophagy in PIK3CA-mutant cancer cells.FOXO3a的亚细胞定位作为PIK3CA突变癌细胞中PI3K和自噬抑制剂联合治疗反应的潜在生物标志物。
Oncotarget. 2017 Jan 24;8(4):6608-6622. doi: 10.18632/oncotarget.14245.
5
Novel chloroquinoline derivatives incorporating biologically active benzenesulfonamide moiety: synthesis, cytotoxic activity and molecular docking.含有生物活性苯磺酰胺部分的新型氯喹啉衍生物：合成、细胞毒性活性及分子对接
Chem Cent J. 2016 Apr 5;10:18. doi: 10.1186/s13065-016-0164-1. eCollection 2016.
6
Enhancement of tumor cell susceptibility to natural killer cell activity through inhibition of the PI3K signaling pathway.通过抑制PI3K信号通路增强肿瘤细胞对自然杀伤细胞活性的敏感性。
Cancer Immunol Immunother. 2016 Mar;65(3):355-66. doi: 10.1007/s00262-016-1804-y. Epub 2016 Feb 16.
7
Evaluation of MicroRNAs Regulating Anoikis Pathways and Its Therapeutic Potential.调控失巢凋亡通路的微小RNA评估及其治疗潜力
Biomed Res Int. 2015;2015:716816. doi: 10.1155/2015/716816. Epub 2015 Oct 26.
8
Pre-clinical study of drug combinations that reduce breast cancer burden due to aberrant mTOR and metabolism promoted by LKB1 loss.针对因LKB1缺失导致的异常mTOR和代谢而减轻乳腺癌负担的药物组合的临床前研究。
Oncotarget. 2014 Dec 30;5(24):12738-52. doi: 10.18632/oncotarget.2818.
9
CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.CDK4/6 抑制剂使 PIK3CA 突变型乳腺癌对 PI3K 抑制剂敏感。
Cancer Cell. 2014 Jul 14;26(1):136-49. doi: 10.1016/j.ccr.2014.05.020. Epub 2014 Jul 4.
10
Dissecting the PI3K Signaling Axis in Pediatric Solid Tumors: Novel Targets for Clinical Integration.解析儿科实体瘤中的 PI3K 信号轴：临床整合的新靶点。
Front Oncol. 2013 Apr 23;3:93. doi: 10.3389/fonc.2013.00093. eCollection 2013.